PPARγ Pro12Ala Pro/Pro and resistin SNP-420 G/G genotypes are synergistically associated with plasma resistin in the Japanese general population

Clinical Endocrinology

Volumn 71, Issue 3, 2009, Pages 341-345

  Osawa, Haruhiko ^a   Tabara, Yasuharu ^a   Kawamoto, Ryuichi ^b   Ohashi, Jun ^b   Ochi, Masaaki ^a   Onuma, Hiroshi ^a   Nishida, Wataru ^a   Yamada, Kazuya ^c   Nakura, Jun ^a   Miki, Tetsuro ^a   Makino, Hideichi ^a   Kohara, Katsuhiko ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c MATSUMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; IMMUNOREACTIVE INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; RESISTIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; INSULIN RESISTANCE; JAPANESE; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; ASIAN; BLOOD; CROSS-SECTIONAL STUDY; GENETICS; MIDDLE AGED; MISSENSE MUTATION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RESISTIN;

EID: 68949203186     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03465.x     Document Type: Article

References (31)

1. DeFronzo, R.A., Bonadonna, R.C. Ferrannini, E. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318 368.
2. McCarthy, M.I. Zeggini, E. (2006) Genetics of type 2 diabetes. Current Diabetes Reports, 6, 147 154.
3. Frayling, T.M. (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nature Reviews Genetics, 8, 657 662.
4. Osawa, H., Onuma, H., Murakami, A. et al. (2002) Systematic search for single nucleotide polymorphisms in the resistin gene: The absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes, 51, 863 866.
5. Osawa, H., Onuma, H., Ochi, M. et al. (2005) Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochemical and Biophysical Research Communications, 335, 596 602.
6. Osawa, H., Yamada, K., Onuma, H. et al. (2004) The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. American Journal of Human Genetics, 75, 678 686.
7. Lehrke, M. Lazar, M.A. (2005) The many faces of PPARγ. Cell, 123, 993 999.
8. Kubota, N., Terauchi, Y., Miki, H. et al 1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell, 4, 597 609.
9. Okuno, A., Tamemoto, H., Tobe, K. et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Journal of Clinical Investigation, 101, 1354 1361.
10. Yamauchi, T., Waki, H., Kamon, J. et al. (2001) Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. Journal of Clinical Investigation, 108, 1001 1013.
11. Altshuler, D., Hirschhorn, J.N., Klannemark, M. et al. (2000) The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics, 26, 76 80.
12. Hara, K., Okada, T., Tobe, K. et al. (2000) The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes. Biochemical and Biophysical Research Communications, 271, 212 216.
13. Mori, H., Ikegami, H., Kawaguchi, Y. et al. (2001) The Pro12 → Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes, 50, 891 894.
14. Deeb, S.S., Fajas, L., Nemoto, M. et al. (1998) A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics, 20, 284 287.
15. Steppan, C. Lazar, M. (2004) The current biology of resistin. Journal of Internal Medicine, 255, 439 447.
16. Steppan, C.M., Bailey, S.T., Bhat, S. et al. (2001) The hormone resistin links obesity to diabetes. Nature, 409, 307 312.
17. Rangwala, S., Rich, A., Rhoades, B. et al. (2004) Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes, 53, 1937 1941.
18. Banerjee, R., Rangwala, S., Shapiro, J. et al. (2004) Regulation of fasted blood glucose by resistin. Science, 303, 1195 1198.
19. Azuma, K., Katsukawa, F., Oguchi, S. et al. (2003) Correlation between serum resistin level and adiposity in obese individuals. Obesity Research, 11, 997 1001.
20. Cho, Y., Youn, B., Chung, S. et al. (2004) Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia, 47, 559 565.
21. Degawa-Yamauchi, M., Bovenkerk, J.E., Juliar, B.E. et al. (2003) Serum resistin (FIZZ3) protein is increased in obese humans. Journal of Clinical Endocrinology and Metabolism, 88, 5452 5455.
22. Fujinami, A., Obayashi, H., Ohta, K. et al. (2004) Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clinica Chimica Acta, 339, 57 63.
23. Lee, J., Chan, J., Yiannakouris, N. et al. (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. Journal of Clinical Endocrinology and Metabolism, 88, 4848 4856.
24. McTernan, P., Fisher, F., Valsamakis, G. et al. (2003) Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Journal of Clinical Endocrinology and Metabolism, 88, 6098 6106.
25. Youn, B., Yu, K., Park, H. et al. (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 89, 150 156.
26. Osawa, H., Tabara, Y., Kawamoto, R. et al. (2007) Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care, 30, 1501 1506.
27. Tokuyama, Y., Osawa, H., Ishizuka, T. et al. (2007) Serum resistin level is associated with insulin sensitivity in Japanese type 2 diabetes. Metabolism, 56, 693 698.
28. Chung, S.S., Choi, H.H., Kim, K.W. et al. (2005) Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein 1 interaction with a common promoter polymorphic site. Diabetologia, 48, 1150 1158.
29. Jung, H.S., Youn, B.S., Cho, Y.M. et al. (2005) The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism, 54, 314 320.
30. Majuri, A., Santaniemi, M., Rautio, K. et al. (2007) Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. European Journal of Endocrinology, 156, 263 269.
31. Chung, S.S., Choi, H.H., Cho, Y.M. et al. (2006) Sp1 mediates repression of the resistin gene by PPARγ agonists in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications, 348, 253 258.